Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,871.20 | 16.50 | 0.19% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,908.71 | 63.58 | -0.27% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 70,037.61 | 1,728.15 | 2.53% |
| NZX 50 Index | 13,675.47 | 5.02 | -0.04% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,696.90 | 14.80 | 0.17% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |